[go: up one dir, main page]

MX2007005611A - Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados. - Google Patents

Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.

Info

Publication number
MX2007005611A
MX2007005611A MX2007005611A MX2007005611A MX2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A
Authority
MX
Mexico
Prior art keywords
sub
imidazo
pyridine compounds
compositions
methods related
Prior art date
Application number
MX2007005611A
Other languages
English (en)
Inventor
Antonio Guglietta
Albert Palomer
Jose Luis Falco
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MX2007005611A publication Critical patent/MX2007005611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a nuevos compuestos de imidazo[1,2-a]piridina de formula general (I) (ver formula (I)): asi como las correspondientes sales farmaceuticamente aceptables; donde R1, R2, R3 y R4 tienen el significado definido en las reivindicaciones. Los compuestos poseen afinidad especifica por el receptor GABAA y son por lo tanto utiles en el tratamiento y prevencion de las enfermedades moduladas por las subunidades a1 y a2 de los receptores GABAA.
MX2007005611A 2004-11-11 2005-11-04 Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados. MX2007005611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105698 2004-11-11
PCT/EP2005/055753 WO2006051063A1 (en) 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto

Publications (1)

Publication Number Publication Date
MX2007005611A true MX2007005611A (es) 2007-07-11

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005611A MX2007005611A (es) 2004-11-11 2005-11-04 Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.

Country Status (24)

Country Link
US (1) US20080200473A1 (es)
EP (1) EP1814880B1 (es)
JP (1) JP2008519805A (es)
KR (1) KR20070084026A (es)
CN (1) CN101065377B (es)
AR (1) AR051626A1 (es)
AT (1) ATE421962T1 (es)
AU (1) AU2005303811A1 (es)
BR (1) BRPI0517796A (es)
CA (1) CA2585315A1 (es)
DE (1) DE602005012598D1 (es)
DK (1) DK1814880T3 (es)
ES (1) ES2321858T3 (es)
IL (1) IL182963A0 (es)
MX (1) MX2007005611A (es)
NO (1) NO20072831L (es)
PA (1) PA8652101A1 (es)
PE (1) PE20060967A1 (es)
PL (1) PL1814880T3 (es)
PT (1) PT1814880E (es)
RU (1) RU2007121864A (es)
TW (1) TWI357412B (es)
UY (1) UY29204A1 (es)
WO (1) WO2006051063A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EP1843734A4 (en) 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
CA2651857A1 (en) * 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
CN101528226B (zh) * 2006-08-24 2012-01-11 澳大利亚核科学技术组织 靶向外周苯二氮卓受体的氟化配体
CA2758424C (en) 2008-04-21 2018-03-06 Signum Biosciences, Inc. Tryptamine derivatives as pp2a methylation modulators
EP2300470A2 (en) * 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
US10478438B2 (en) 2008-10-16 2019-11-19 David Reed Helton Treatment of organophosphate exposure with ocinaplon
US20120010188A1 (en) * 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
BR112012010752B1 (pt) 2009-11-05 2021-07-20 University Of Notre Dame Du Lac Compostos imidazo[1,2-a]piridina
WO2012036278A1 (ja) 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
JP7055378B2 (ja) 2015-09-17 2022-04-18 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
EP3917529A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
MX2022009309A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de los mismos.
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
KR20260004434A (ko) * 2023-04-24 2026-01-08 상하이 에스아이엠알 바이오테크놀로지 컴퍼니 리미티드 이미다조피리딘 또는 이미다조피라진 화합물, 이의 제조 방법, 약학 조성물 및 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
ATE62687T1 (de) * 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
WO2004066930A2 (en) * 2003-01-27 2004-08-12 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Also Published As

Publication number Publication date
CN101065377B (zh) 2011-07-27
ES2321858T3 (es) 2009-06-12
JP2008519805A (ja) 2008-06-12
UY29204A1 (es) 2006-01-31
TW200624432A (en) 2006-07-16
ATE421962T1 (de) 2009-02-15
US20080200473A1 (en) 2008-08-21
CA2585315A1 (en) 2006-05-18
IL182963A0 (en) 2007-08-19
WO2006051063A1 (en) 2006-05-18
NO20072831L (no) 2007-08-01
EP1814880A1 (en) 2007-08-08
PL1814880T3 (pl) 2009-07-31
AR051626A1 (es) 2007-01-24
DK1814880T3 (da) 2009-05-18
KR20070084026A (ko) 2007-08-24
CN101065377A (zh) 2007-10-31
PA8652101A1 (es) 2006-10-13
EP1814880B1 (en) 2009-01-28
PT1814880E (pt) 2009-04-23
BRPI0517796A (pt) 2008-10-28
DE602005012598D1 (de) 2009-03-19
PE20060967A1 (es) 2006-09-20
TWI357412B (en) 2012-02-01
RU2007121864A (ru) 2008-12-20
AU2005303811A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MX2007005611A (es) Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
WO2007138472A3 (en) Triazolopyridazine derivatives
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
MEP23808A (en) Pyridine[3,4-b]pyrazinones
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
WO2006011050A3 (en) Pyridine derivatives
WO2009023844A3 (en) 3' substituted compounds having 5-ht6 receptor affinity
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
UA99447C2 (ru) Способ получения силденафила
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
WO2007147771A3 (en) Tetralin and indane derivatives and uses thereof
WO2008147812A3 (en) 4' substituted compounds having 5-ht6 receptor affinity
WO2008101247A3 (en) 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
WO2010011546A3 (en) Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity
WO2004075840A3 (en) Selective non-steroidal glucocorticoid receptor modulators
WO2004093805A3 (en) Selective spirocyclic glucocorticoid receptor modulators
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2007017728A3 (en) Novel heterocyclic compounds
TW200514785A (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
TW200510422A (en) N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides and compositions and methods related thereto

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general